Preview

User

Not a user? Register with this site Forgot your password?

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

The use of Perampanel suspension in clinical practice for children and adolescents with epilepsy: a compilation of insights from Russian experts

https://doi.org/10.14412/2074-2711-2026-3-57-66

Abstract

Objective: to evaluate the efficacy and tolerability of perampanel suspension (Fycompa®) in real-world clinical practice among children and adolescents with epilepsy in a cohort of Russian patients.

Material and methods. A retrospective multicenter analysis was conducted of depersonalized data from 80 patients from 27 centres (40 boys, 40 girls) aged between 4–18 years (mean age 8.2 years) with various forms of epilepsy who received perampanel suspension (PER) as adjunctive therapy. Inclusion criteria were a verified diagnosis of epilepsy consistent with the drug's approved indications, and the availability of data on seizure frequency prior to treatment and after 1–3 months of therapy. To assess efficacy after 3–6 months, data were used from patients who continued treatment and had corresponding records. Statistical analysis was performed using descriptive statistical methods. The primary outcome measures were changes in seizure frequency after 1–3 and 3–6 months of therapy, the proportion of responders, the rate of remission, and adverse events (AEs).

Results. After 1–3 months of treatment, the highest efficacy was observed in isolated bilateral tonic-clonic seizures (BTCS; remission – 78.5%, overall response rate – 89.2%) and generalised tonic-clonic seizures (GTCS; remission – 71.4%, overall response rate – 100%). For focal seizures (FS) without progression to BTCS, remission was 38%, and the overall response rate was 71%. In FS progressing to BTCS, remission was recorded in 37.5% of patients, with an overall response rate of 62.5%. In patients with a combination of these seizure types and other types of seizures, a reduction in the frequency of concomitant seizures was also observed. At the 3–6-month stage, an additional response (remission or a ≥50% reduction in seizure frequency) was observed in only a small proportion of patients (for example, additional remission in FS without BTCS was observed in 10.3% of patients). The drug demonstrated reasonably good tolerability: AEs were reported in 16.3% of patients after 1–3 months, and the need for discontinuation was 2.5%.

Conclusion. The PER suspension is well tolerated and effective in children aged 4 years and older with FS, with or without progression to BTCS, and in children aged 7 years and older with GTCS, including patients weighing less than 30 kg. The liquid formulation allows for precise dose titration and is convenient to administer, particularly in patients with dysphagia.

About the Authors

A. M. Pivovarova
Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

Alexandra Mikhailovna Pivovarova 

2, Taldomskaya St., Moscow 125412
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



Yu. A. Aleksandrov
Homeopathic Practice Medical Center
Russian Federation

138, Kalinina St., Khabarovsk 680028
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



Yu. V. Bazhanova
Far Eastern Center of Clinical Neurology Nevrodom
Russian Federation

138, Kalinina St., Khabarovsk 680028
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



M. V. Barkhatov
Federal Siberian Clinical Research Center, FMBA of Russia
Russian Federation

26, Kolomenskaya St., Krasnoyarsk 660037
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



O. V. Belyaev
Department of Neurology, Psychiatry, Manual Medicine and Medical Rehabilitation, Institute of Continuing Medical and Pharmaceutical Education, Volgograd State Medical University, Ministry of Health of Russia ; Medical Center “Epicenter”
Russian Federation

1, Pavshikh Bortsov Sq., Volgograd 400066

92, V.I. Lenina Prosp., Volgograd 400005
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



T. E. Volskaya
Consultative and Diagnostic Center, Leningrad Regional Children's Clinical Hospital ; Almadeya Clinic of Rehabilitation Medicine
Russian Federation

6, Komsomola St., St. Petersburg 195009

68, Toreza Prosp., St. Petersburg 194223
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



E. K. Gorbunova
Neuromed Clinic, Center for Neurology and Paroxysmal Disorders ; Regional Clinical Hospital of the Kaliningrad Region
Russian Federation

36, Chaikovskogo St., Kaliningrad 236022

74, Klinicheskaya St., Kaliningrad 236016
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



Z. K. Gorchkhanova
Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery, Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

2, Taldomskaya St., Moscow 125412
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



A. I. Grechikhina
Children's Consultative and Diagnostic Center, Regional Children's Clinical Hospital ; Alpha Rhythm Medical Center
Russian Federation

32, S. Deryabinoi St., Yekaterinburg 620149

3, Ukhtomskaya St., Yekaterinburg 620036
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



D. I. Gukosyan
A.A. Kazaryan Center of Epileptology and Neurology
Russian Federation

64, Lenina St., Krasnodar 350000
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



E. V. Gumennyk
EpiJay Clinic of Neurology and Epileptology
Russian Federation

17–19, Radishcheva St., St. Petersburg 191014
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



D. N. Dunin
Department of Pediatric Neurology, Kazan State Medical Academy – Branch of the Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia ; NEO Medical Center
Russian Federation

36, Butlerova St., Kazan 420012

13, Sibirsky Trakt St., Kazan 420029
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



I. V. Volkov
St. Valentine Epileptology Center
Russian Federation

5, Vokzalnaya Magistral, Novosibirsk 630004
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



O. K. Volkova
St. Valentine Epileptology Center ; City Children's Clinical Emergency Hospital
Russian Federation

5, Vokzalnaya Magistral, Novosibirsk 630004

3, Krasny Prosp., Novosibirsk 630011
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



N. L. Kim
Regional Epileptology Center, Regional Consultative and Diagnostic Center ; Department of Personalized and Translational Medicine, Rostov State Medical University, Ministry of Health of Russia
Russian Federation

127, Pushkinskaya St., Rostov-on-Don 344000

29, Nakhichevansky Lane, Rostov-on-Don 344022
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



Yu. T. Kim
Immunorehabilitation Center Medical Center
Russian Federation

39, Gogolya St., Khabarovsk 680011
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



O. V. Koroleva
Irkutsk Regional Center for AIDS Prevention and Control and Infectious Diseases
Russian Federation

11, Spartakovskaya St., Irkutsk 664035
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



N. V. Muzhikina
Center of Epileptology and Video-EEG Monitoring, Institute of Human Brain, Russian Academy of Sciences
Russian Federation

12A, Akademika Pavlova St., St. Petersburg 197022
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



E. N. Paramonova
Center of Epilepsy, Paroxysmal Disorders and Sleep Disorders
Russian Federation

48, Ippodromskaya St., Novosibirsk 630111
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



G. S. Pilina
Palladium Center of Modern Neurology and Diagnostics
Russian Federation

36, Dzerzhinskogo St., Izhevsk 426039
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



I. V. Ponomareva
Polyclinic No. 2, Regional Clinical Hospital No. 3 ; Center of Neurology and Sleep Medicine
Russian Federation

376V, Pobedy Prosp., Chelyabinsk 454021

33D, Komsomolsky Prosp., Chelyabinsk 454000
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



M. A. Provatorova
Department of Physical, Rehabilitation and Integrative Medicine, Research Clinical Institute of Childhood of the Moscow Region
Russian Federation

23A, Akademika Kargina St., Mytishchi 141009
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



O. A. Rakhmanina
Department of Childhood Diseases and Outpatient Pediatrics, Tyumen State Medical University, Ministry of Health of Russia ; Regional Treatment and Rehabilitation Center
Russian Federation

54, Odesskaya St.,Tyumen 625023

11/2, Shchorsa St., Tyumen 625048
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



N. N. Savelyeva
V.D. Seredavin Samara Regional Clinical Hospital ; Department of Neurology and Neurosurgery, Samara State Medical University, Ministry of Health of Russia
Russian Federation

159, Tashkentskaya St., Samara 443095

89, Chapaevskaya St., Samara 443099
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



Yu. V. Saiko
Biomed Expert Rehabilitation Medical Center
Russian Federation

11A, Narodny Prosp., Vladivostok 690014
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



T. R. Tomenko
Ural State Medical University, Ministry of Health of Russia ; UGMK-Health European Medical Center ; Ural Federal University named after the First President of Russia B.N. Yeltsin
Russian Federation

3, Repina St., Yekaterinburg 620028

113, Sheinkmana St., Yekaterinburg 620144

19, Mira St., Yekaterinburg 620002
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



R. F. Torres-Zuev
Scientific and Practical Center of Pediatric Psychoneurology, Moscow Healthcare Department
Russian Federation

74, Michurinsky Prosp., Moscow 119602
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



T. M. Khokhryakova
Epicenter Clinic of Neurology and Epilepsy
Russian Federation

6, Sovetskoi Armii St., Perm 614066
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



N. V. Chebanenko
Department of Pediatric Neurology, Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia
Russian Federation

2/1, Barrikadnaya St., Build. 1, Moscow 125993
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



A. V. Yatsenko
EpiJay Clinic of Neurology and Epileptology
Russian Federation

17–19, Radishcheva St., St. Petersburg 191014
Competing Interests:

The first author received an honorarium for her contribution to the publication. The conflict of interests did not affect the results of the study



References

1. Mukhin KYu, Pylaeva OA, Bobylova MYu, Glukhova LYu. New possibilities of using perampanel in children. Efficacy and tolerability of perampanel in the treatment of epilepsy (literature review and experience of Svt. Luka’s Association of Medical Institutions). Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology. 2024;19(3):8-32 (In Russ.). doi: 10.17650/2073-8803-2024-19-3-8-32

2. Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24. doi: 10.1111/ane.12100

3. General Product Characteristics of Fycompa® (perampanel), 0.5 mg/ml, oral suspension. RU LP-No. (006530)-(RG-RU) (In Russ.).

4. General Product Characteristics (SmPC) of Fycompa® (perampanel), film-coated tablets. RU LP-No. (000644)-(RG-RU) (In Russ.).

5. Fogarasi A, Flamini R, Milh M, et al. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures. Epilepsia. 2020;61(1):125-37. doi: 10.1111/epi.16413

6. Flamini R, Fogarasi A, Omatsu H, et al. Long-term safety and efficacy of adjunctive perampanel in pediatric patients (ages 4 to <12 years) with inadequately controlled focal-onset seizures or generalized tonic-clonic seizures. Epilepsia. 2025 Apr;66(4):1097-109. doi: 10.1111/epi.18242

7. Bakhtin IS, Belousova ED. Use of perampanel suspension in children (clinical case). Epilepsiya i paroksizmal'nyye sostoyaniya. 2025; (in press) (In Russ.).

8. Laurenza A, Hall N, Majid O, Rege B. Bioequivalence evaluation of perampanel oral suspension and tablet formulations in healthy subjects: A phase I, open-label, crossover study (P3.240). Neurology. 2017;88(16 Suppl).

9. Rakhmanina OA, Volkov IV, Volkova OK, et al. The first combined Russian experience of using perampanel in children and adolescents with epilepsy in everyday clinical practice. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology. 2022;17(2):8-20 (In Russ.). doi: 10.17650/2073-8803-2022-17-1-8-20

10. Weng Y, Ma B, Lin X. Real-world effectiveness and safety of perampanel for children and adolescents with epilepsy: A meta-analysis with at least 1-year follow-up. Seizure. 2024;122:96-104. doi: 10.1016/j.seizure.2024.09.014

11. Shi X, Lu X, Li L, et al. Perampanel as Add-on in Patients Aged ≥ 12 Years with Focal Epilepsy: A Prospective Real-World Observational Study from Southern China. Neurol Ther. 2025;14(4):1521-37. doi: 10.1007/s40120-025-00760-8


Review

For citations:

Pivovarova AM, Aleksandrov YA, Bazhanova YV, Barkhatov MV, Belyaev OV, Volskaya TE, Gorbunova EK, Gorchkhanova ZK, Grechikhina AI, Gukosyan DI, Gumennyk EV, Dunin DN, Volkov IV, Volkova OK, Kim NL, Kim YT, Koroleva OV, Muzhikina NV, Paramonova EN, Pilina GS, Ponomareva IV, Provatorova MA, Rakhmanina OA, Savelyeva NN, Saiko YV, Tomenko TR, Torres-Zuev RF, Khokhryakova TM, Chebanenko NV, Yatsenko AV. The use of Perampanel suspension in clinical practice for children and adolescents with epilepsy: a compilation of insights from Russian experts. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2026;18(3):57-66. (In Russ.) https://doi.org/10.14412/2074-2711-2026-3-57-66

Views: 296

JATS XML


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)

"IMA-PRESS" LLC 
115093, Russian Federation, Moscow,
Partijnyj per, 1, bld. 58, of. 745
E-mail: info@ima-press.net
Phone: +7(495) 926-7814

Processing of personal data
supported by NEICON (Elpub lab)